Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

VJVirtual | Emerging immunotherapies for AML

Naval Daver • 17 Apr 2020
Acute Lymphoblastic Leukemia Acute Myeloid Leukemia Leukemia Antibodies Blinatumomab Durvalumab Flotetuzumab Nivolumab Pembrolizumab

Naval Daver, MD, University of Texas MD Anderson Cancer Center, Houston, TX, outlines the emerging immunotherapies for acute myeloid leukemia (AML). Specifically, T-cell enhancing therapies, macrophage-enhancing agents, bispecific antibodies and CAR-T cells are discussed. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Naval Daver

New treatments in AML: FLT3 inhibitors & novel combinations
Gail Roboz et al. • 4 Sep 2023
3:53
Investigating the combination of pivekimab sunirine, azacitidine & venetoclax in R/R AML
Naval Daver • 12 Dec 2022
1:13
The importance of CD47 as a target in MDS and AML
Naval Daver • 12 Dec 2022
3:50
Investigating the safety & efficacy of magrolimab, azacitidine & venetoclax in patients with AML
Naval Daver • 12 Dec 2022

Related Videos

2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
1:48
Do all patients require maintenance therapy following alloSCT?
Mark Levis • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals